COVID-19 Immunotherapy Collab at UGA with Biotech Firm CEL-SCI to Fight Coronavirus
NewswiseCEL-SCI’s immunotherapy candidate aims to treat patients at highest risk of dying from COVID-19. LEAPS immunotherapy has been used in collaboration with the National Institutes for Allergies and Infectious Diseases (NIAID) against another respiratory virus, H1N1, involved in the 2009 H1N1 flu pandemic. Those successful studies demonstrated that LEAPS peptides, given after virus infection has occurred, reduced morbidity and mortality in mice infected with H1N1.